vs
EURONET WORLDWIDE, INC.（EEFT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
EURONET WORLDWIDE, INC.的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 4.7%，领先8.1%），EURONET WORLDWIDE, INC.同比增速更快（5.9% vs 5.9%），EURONET WORLDWIDE, INC.自由现金流更多（$434.3M vs $161.8M），过去两年EURONET WORLDWIDE, INC.的营收复合增速更高（13.7% vs 9.0%）
Euronet Worldwide是总部位于美国堪萨斯州利伍德的全球电子支付服务提供商，业务涵盖自动柜员机（ATM）、销售点（POS）服务、信用卡/借记卡服务、货币兑换及其他电子金融服务与支付软件，旗下拥有Transact、PaySpot、epay等多家预付费业务子公司。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EEFT vs RVTY — 直观对比
营收规模更大
EEFT
是对方的1.4倍
$772.1M
营收增速更快
EEFT
高出0.0%
5.9%
净利率更高
RVTY
高出8.1%
4.7%
自由现金流更多
EEFT
多$272.5M
$161.8M
两年增速更快
EEFT
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $51.8M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 9.1% | 14.5% |
| 净利率 | 4.7% | 12.7% |
| 营收同比 | 5.9% | 5.9% |
| 净利润同比 | 14.3% | 3.9% |
| 每股收益（稀释后） | $0.97 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EEFTRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $915.5M | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $986.2M | $691.7M | ||
| Q1 24 | $857.0M | $649.9M |
净利润EEFTRVTY
| Q4 25 | $51.8M | $98.4M | ||
| Q3 25 | $122.0M | $46.7M | ||
| Q2 25 | $97.6M | $53.9M | ||
| Q1 25 | $38.4M | $42.2M | ||
| Q4 24 | $45.3M | $94.6M | ||
| Q3 24 | $151.5M | $94.4M | ||
| Q2 24 | $83.1M | $55.4M | ||
| Q1 24 | $26.2M | $26.0M |
毛利率EEFTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率EEFTRVTY
| Q4 25 | 9.1% | 14.5% | ||
| Q3 25 | 17.0% | 11.7% | ||
| Q2 25 | 14.8% | 12.6% | ||
| Q1 25 | 8.2% | 10.9% | ||
| Q4 24 | 11.7% | 16.3% | ||
| Q3 24 | 16.6% | 14.3% | ||
| Q2 24 | 13.6% | 12.4% | ||
| Q1 24 | 7.5% | 6.8% |
净利率EEFTRVTY
| Q4 25 | 4.7% | 12.7% | ||
| Q3 25 | 10.6% | 6.7% | ||
| Q2 25 | 9.1% | 7.5% | ||
| Q1 25 | 4.2% | 6.4% | ||
| Q4 24 | 4.3% | 13.0% | ||
| Q3 24 | 13.8% | 13.8% | ||
| Q2 24 | 8.4% | 8.0% | ||
| Q1 24 | 3.1% | 4.0% |
每股收益（稀释后）EEFTRVTY
| Q4 25 | $0.97 | $0.86 | ||
| Q3 25 | $2.75 | $0.40 | ||
| Q2 25 | $2.27 | $0.46 | ||
| Q1 25 | $0.85 | $0.35 | ||
| Q4 24 | $0.96 | $0.77 | ||
| Q3 24 | $3.21 | $0.77 | ||
| Q2 24 | $1.73 | $0.45 | ||
| Q1 24 | $0.55 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $919.9M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $6.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资EEFTRVTY
| Q4 25 | $1.0B | $919.9M | ||
| Q3 25 | $1.2B | $931.4M | ||
| Q2 25 | $1.3B | $991.8M | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.2B | $1.7B |
总债务EEFTRVTY
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.3B | — |
股东权益EEFTRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产EEFTRVTY
| Q4 25 | $6.5B | $12.2B | ||
| Q3 25 | $6.3B | $12.1B | ||
| Q2 25 | $6.6B | $12.4B | ||
| Q1 25 | $6.1B | $12.4B | ||
| Q4 24 | $5.8B | $12.4B | ||
| Q3 24 | $6.3B | $12.8B | ||
| Q2 24 | $6.1B | $13.4B | ||
| Q1 24 | $5.7B | $13.4B |
负债/权益比EEFTRVTY
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 0.92× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 1.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $559.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $434.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 39.2% | 21.0% |
| 资本支出强度资本支出/营收 | 11.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 10.81× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $722.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流EEFTRVTY
| Q4 25 | $559.8M | $182.0M | ||
| Q3 25 | $197.3M | $138.5M | ||
| Q2 25 | $182.9M | $134.3M | ||
| Q1 25 | $1.7M | $128.2M | ||
| Q4 24 | $732.8M | $174.2M | ||
| Q3 24 | $440.3M | $147.9M | ||
| Q2 24 | $182.2M | $158.6M | ||
| Q1 24 | $30.0M | $147.6M |
自由现金流EEFTRVTY
| Q4 25 | $434.3M | $161.8M | ||
| Q3 25 | $161.2M | $120.0M | ||
| Q2 25 | $148.3M | $115.5M | ||
| Q1 25 | $-21.5M | $112.2M | ||
| Q4 24 | $615.6M | $149.8M | ||
| Q3 24 | $414.5M | $125.6M | ||
| Q2 24 | $148.8M | $136.6M | ||
| Q1 24 | $6.2M | $129.7M |
自由现金流率EEFTRVTY
| Q4 25 | 39.2% | 21.0% | ||
| Q3 25 | 14.1% | 17.2% | ||
| Q2 25 | 13.8% | 16.0% | ||
| Q1 25 | -2.3% | 16.9% | ||
| Q4 24 | 58.8% | 20.5% | ||
| Q3 24 | 37.7% | 18.4% | ||
| Q2 24 | 15.1% | 19.7% | ||
| Q1 24 | 0.7% | 20.0% |
资本支出强度EEFTRVTY
| Q4 25 | 11.3% | 2.6% | ||
| Q3 25 | 3.2% | 2.6% | ||
| Q2 25 | 3.2% | 2.6% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 11.2% | 3.4% | ||
| Q3 24 | 2.3% | 3.3% | ||
| Q2 24 | 3.4% | 3.2% | ||
| Q1 24 | 2.8% | 2.7% |
现金转化率EEFTRVTY
| Q4 25 | 10.81× | 1.85× | ||
| Q3 25 | 1.62× | 2.97× | ||
| Q2 25 | 1.87× | 2.49× | ||
| Q1 25 | 0.04× | 3.03× | ||
| Q4 24 | 16.18× | 1.84× | ||
| Q3 24 | 2.91× | 1.57× | ||
| Q2 24 | 2.19× | 2.87× | ||
| Q1 24 | 1.15× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EEFT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
